EMIS - odd they don't give HbA1c decrease for the other doses , although they do say the HbA1c showed a dose response.
They also said, "We believe that these results will support our efforts to partner this program with a major pharmaceutical company. Finally while the phase 2 study was being conducted we tested several new oral insulin formulations in humans, which are more efficient in delivering insulin as compared to the formulation used in the phase 2." Dr. Goldberg concluded."
Which implies they aren't satisfied with the results.
Market Data 
Markets 
AI
